Latest Breaking News On - பீட்டர் டோவர்டீ நிறுவனம் க்கு தொற்று - Page 8 : comparemela.com

Researchers have demonstrated that it is possible to use the CRISPR gene-editing tool to stop SARS-CoV-2, the virus responsible for COVID-19, from replicating in infected human cells. The demonstration was done in culture cells in the lab so it is not a forthcoming treatment yet, but this approach could be revolutionary in the medium and long term. As reported in Nature Communications, the team used the enzyme CRISPR-Cas13b to bind itself to the part of the virus’ genetic code – its RNA – used for replication. The enzyme degrades this bit of information leaving the virus unable to replicate.   “The flexibility of CRISPR-Cas13 – which only needs the viral sequence – means we can look to rapidly design antivirals for COVID-19 and any new emerging viruses,” senior author Professor Sharon Lewin, from the Peter Doherty Institute for Infection and Immunity in Australia, said in a statement.

Emmanuelle charpentierMohamed farehSharon lewinJennifer doudnaNature communicationsUniversity of melbournePeter doherty institute for infectionProfessor sharon lewinPeter doherty instituteஇம்மானுவேல் சார்பென்டிர்ஷரோன் லெவின்இயற்கை தகவல்தொடர்புகள்பல்கலைக்கழகம் ஆஃப் மெல்போர்ன்பீட்டர் டோவர்டீ நிறுவனம் க்கு தொற்றுப்ரொஃபெஸர் ஷரோன் லெவின்பீட்டர் டோவர்டீ நிறுவனம்